BG-75202 features among several projects starting first-in-human trials.
ApexOnco Front Page
Recent articles
Inhibrx reveals three deaths in phase 1, but all predate screening protocols.
The group reports responses with its CD123-targeting ADC, but cash is running short.
Mevrometostat is the only EZH2 inhibitor in phase 3 for prostate cancer.
GDC-7035 enters the clinic, as does another bispecific against PD-L1 and VEGF.
The first approval for TAR-200 is on the horizon, setting up a challenge to Keytruda.
The next-generation telisotuzumab adizutecan joins teliso-V in late-stage development.
The company’s CEACAM5 and PRMT5 projects feature among the latest first-in-human entrants.
